Abstract Number: 1930 • 2018 ACR/ARHP Annual Meeting
Histologic and Transcriptional Evidence of Subclinical Synovial Inflammation in Rheumatoid Arthritis Patients in Clinical Remission
Background/Purpose: Rheumatoid Arthritis (RA) patients in clinical remission may still develop structural damage that has been attributed to ongoing synovial inflammation, sometimes only detectable…Abstract Number: 1931 • 2018 ACR/ARHP Annual Meeting
Abundance of Plasma Microbial Small RNAs Are Predictive of Improvement in Disease Activity after DMARD Initiation for Rheumatoid Arthritis
Background/Purpose: Small RNAs (sRNAs) are important regulators of biological processes and are potential biomarkers of disease and drug response. We previously found that microbial sRNAs…Abstract Number: 1932 • 2018 ACR/ARHP Annual Meeting
Complications Following Total Knee Arthroplasty in Inflammatory Versus Osteoarthritis
Background/Purpose: TKA is commonly performed in patients with a history of inflammatory arthritis. These patients are likely at higher risk of complications, from both the…Abstract Number: 1933 • 2018 ACR/ARHP Annual Meeting
Histological Features and Tissue-Macrophage Phenotype of Synovial Biopsies Identify RA Patients in Sustained Remission at Risk of Disease Flare after Treatment Tapering or Discontinuation
Background/Purpose: Flares of immune-mediated inflammatory diseases, as Rheumatoid Arthritis (RA) occur unpredictably representing a major burden for patients and clinicians. We aimed to dissect the…Abstract Number: 1934 • 2018 ACR/ARHP Annual Meeting
microRNA Targeting IL-33 Gene As Biomarker to Predict Subclinical Atherosclerosis in Patients with Early Rheumatoid Arthritis
Background/Purpose: Patients with RA had increased risk of cardiovascular disease (CVD). Interleukin 33 (IL-33) plays an important role in pathogenesis of RA and development of…Abstract Number: 1935 • 2018 ACR/ARHP Annual Meeting
Multiple Dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP5094, an Anti-Alpha9 Integrin Monoclonal Antibody, in Patients with Rheumatoid Arthritis on Methotrexate
Background/Purpose: Joint synovium is the main tissue involved in rheumatoid arthritis (RA) lesions. Alpha9 integrin is expressed by synovial tissue lining cells and has been…Abstract Number: 1936 • 2018 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
Background/Purpose: GP2017, a proposed adalimumab biosimilar, matched reference adalimumab (refADL) in preclinical and pharmacokinetics studies.1,2 The confirmatory efficacy and safety study in patients with plaque-type…Abstract Number: 1937 • 2018 ACR/ARHP Annual Meeting
Low-Dose IL-2 Restored Reduced Regulatory T Cells in Patients with Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) have lymphocyte dysfunction characterized by deficiency or dysfunction of regulatory T cells (Tregs), which plays crucial roles in immune tolerance. Low dose IL-2…Abstract Number: 1938 • 2018 ACR/ARHP Annual Meeting
A Phase IIb Dose-Ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the efficacy…Abstract Number: 1939 • 2018 ACR/ARHP Annual Meeting
Sirolimus Treatment in Patients with Refractory Rheumatoid Arthritis: A Double-Arm, Open-Label, phase1/2 Trail
Background/Purpose: Patients with refractory rheumatoid arthritis (RA) have T-cell dysfunction that associates the activation of mTOR that is inhibited by rapamycin, which has been developed…Abstract Number: 1940 • 2018 ACR/ARHP Annual Meeting
Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety
Background/Purpose: In sarilumab randomized controlled trials (RCTs), dose delay and/or reduction was recommended for management of patients who developed neutropenia Grade (G) 3 (ANC ≥500…Abstract Number: 1941 • 2018 ACR/ARHP Annual Meeting
Altered Cognitive Function in Systemic Lupus Erythematosus and Associations with Inflammation and Functional Brain Changes
Background/Purpose: Cognitive dysfunction is a common problem in systemic lupus erythematosus (SLE) but the cause is still unclear; measuring it can be difficult and, as…Abstract Number: 1942 • 2018 ACR/ARHP Annual Meeting
Anti-NMDA Receptor Antibodies in Systemic Lupus Erythematosus Associate with Decreased White Matter Integrity and Impaired Spatial Memory
Background/Purpose: Cognitive impairment is common in SLE and impacts quality of life; however, causality is limited by incomplete understanding of neurotoxic mechanisms. Diffusion tensor imaging…Abstract Number: 1943 • 2018 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Associate with Poor Renal Outcomes, Damage Accrual, and Death: A Prospective Ghanaian SLE Cohort
Background/Purpose: Two Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, are enriched in ancestrally African populations due to a conferred superior resistance to Trypanosoma…Abstract Number: 1944 • 2018 ACR/ARHP Annual Meeting
Does Renin Angiotensin System Blockade in Addition to Immunosuppressive Therapy Improve Proteinuria in Acute Lupus Nephritis?
Background/Purpose: Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are currently recommended for patients with lupus nephritis (LN) as an adjunctive therapy for…
ACR Meeting Abstracts